Contact Supplier

Contact Supplier

To get in touch with ARTES Biotechnology GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    ARTES partners with Basic Pharma to advance recombinant protein production

    news-releasesARTES Biotechnology GmbH
    October 18th 2023

    Langenfeld, Germany: –Specialist in microbial process development and technology transfer for the pharmaceutical industry, ARTES Biotechnology GmbH (ARTES), has forged a strategic Collaboration and Co-Marketing Partnership with Netherlands-based Basic Pharma, aiming to advance pharmaceutical recombinant protein production.

    The partnership will combine ARTES expertise in development and transfer of recombinant cell lines and protein production processes from microbial expression systems with Basic Pharma’s specialized focus on niche pharmaceutical products.

    Streamlined supply chain

    The overarching objective of the alliance is to establish a streamlined supply chain that cuts time-to-market for new pharmaceutical products.

    Under the terms of this collaboration agreement, ARTES and Basic Pharma will harness their respective expertise, cutting-edge technologies, and marketing strategies for the development and production of non-GMP recombinant proteins as a first step. This initial phase will pave the way for subsequent upgrades to meet Good Manufacturing Practice (GMP) pharmaceutical standards.

    The inaugural product to emerge from this collaboration is Human Serum Albumin (HSA), derived from the Hansenula polymorpha yeast. The HSA initiative is partially funded by EU BioMan4R2 project within the European SMP COSME program, focusing on EU resilience efforts in the health field on Biomanufacturing and MedTech areas (BMT).

    Research reagents

    ARTES Biotechnology’s Managing Director, Dr. Michael Piontek, commented: “This alliance marks the first step in realizing our new strategy offering research reagents for non-human applications. Together with Basic Pharma, today we start with HSA produced from our proprietary yeast Hansenula. Tomorrow, we will expand this portfolio with further enzymes, antigens and functional proteins.”

    Ralph Bosmans, Manager of Biotechnology at Basic Pharma, expressed his enthusiasm for the collaboration: “We are delighted to join forces with ARTES Biotechnology on this venture. The synergy between ARTES Biotechnology’s proficiency in recombinant cell line development and our experience in pharmaceutical development is a perfect match.”

    Bob Kool, Managing Director at Basic Pharma, further emphasized: “We are excited to embark on this strategic journey alongside ARTES Biotechnology. The fusion of our pharmaceutical development experience with their cutting-edge protein production expertise promises a dynamic partnership.”

    About ARTES Biotechnology

    ARTES Biotechnology GmbH is a Germany-based company specialized in recombinant protein production, process and vaccine (VLP-based) development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld.

    Learn more at:

    About Basic Pharma

    Founded in 2003 and headquartered in Geleen, The Netherlands, Basic Pharma is a pharmaceutical company focused on the development, production, licensing, and registration of pharmaceutical niche products. The company offers a range of services, including contract manufacturing, formulation development, regulatory support, and analytical services, sold worldwide.

    In 2020, Basic Pharma expanded its portfolio by inaugurating a dedicated biotechnology department focusing on the production of biologicals. This department is suitably equipped for microbial fermentation and protein purification, thereby facilitating the development and production of recombinant proteins.

    Further information at:

    About BioMan4R2

    The BioMan 4R2 project within the European SMP COSME program offers financial support and networking for small and medium-sized companies in the biological products and medical technology manufacturing sectors that want to increase their resilience, sustainability, and competitiveness.

    Further information at:


    Click on Fine Art of Biotechnology  to learn more about the work of ARTES Biotechnology.


    ARTES Biotechnology is a globally working, well established and reliable technology provider for recombinant protein production.

    ARTES partners with Basic Pharma to advance recombinant protein production

    ARTES Biotechnology/BasicPharma.

    Contact ARTES Biotechnology GmbH

    Simply fill out the form below to contact ARTES Biotechnology GmbH now.

    Send ARTES Biotechnology GmbH a Message